<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Radioimmunotherapy using (90)Y-ibritumomab tiuxetan has predominantly been used in patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, but little is known about its activity in patients with extranodal marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of the mucosa associated lymphoid tissue (MALT) </plain></SENT>
<SENT sid="1" pm="."><plain>A total of six patients progressing/relapsing following conventional therapy for MALT <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were treated with (90)Y-ibritumomab tiuxetan at our institution </plain></SENT>
<SENT sid="2" pm="."><plain>Two patients had gastric MALT <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, one suffered from orbital MALT <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and two had cutaneous MALT <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, while one patient had a widely disseminated <z:hpo ids='HP_0002665'>lymphoma</z:hpo> involving the stomach, lungs, lymph nodes, and salivary glands </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were at least in third relapse following various forms of therapy including Helicobacter pylori-eradication, radiation, chemotherapy, and application of rituximab </plain></SENT>
<SENT sid="4" pm="."><plain>Following two doses of rituximab at 250 mg/m(2) at an interval of 1 week, (90)Y-ibritumomab tiuxetan was given immediately at a dose of 0.4 mCi/kg body weight </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment was well tolerated apart from one episode of <z:hpo ids='HP_0002090'>pneumonia</z:hpo> requiring hospitalization </plain></SENT>
<SENT sid="6" pm="."><plain>Four patients developed a complete remission (ongoing now for 4, 16, 23, and 24 months), one patient had a partial response lasting for 5 months, and one patient had stable disease for 13 months </plain></SENT>
<SENT sid="7" pm="."><plain>After a follow-up of 9-29 months, <z:hpo ids='HP_0000001'>all</z:hpo> patients are alive </plain></SENT>
<SENT sid="8" pm="."><plain>Application of (90)Y-ibritumomab tiuxetan is active and safe in heavily pretreated patients with MALT <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>